Back to Search
Start Over
Improving the Efficacy of Regulatory T Cell Therapy
- Source :
- Clinical Reviews in Allergy & Immunology
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Autoimmunity is caused by an unbalanced immune system, giving rise to a variety of organ-specific to system disorders. Patients with autoimmune diseases are commonly treated with broad-acting immunomodulatory drugs, with the risk of severe side effects. Regulatory T cells (Tregs) have the inherent capacity to induce peripheral tolerance as well as tissue regeneration and are therefore a prime candidate to use as cell therapy in patients with autoimmune disorders. (Pre)clinical studies using Treg therapy have already established safety and feasibility, and some show clinical benefits. However, Tregs are known to be functionally impaired in autoimmune diseases. Therefore, ex vivo manipulation to boost and stably maintain their suppressive function is necessary when considering autologous transplantation. Similar to autoimmunity, severe coronavirus disease 2019 (COVID-19) is characterized by an exaggerated immune reaction and altered Treg responses. In light of this, Treg-based therapies are currently under investigation to treat severe COVID-19. This review provides a detailed overview of the current progress and clinical challenges of Treg therapy for autoimmune and hyperinflammatory diseases, with a focus on recent successes of ex vivo Treg manipulation.
- Subjects :
- Allergy
Regulatory T cell
AUTOIMMUNE ENCEPHALOMYELITIS
Autoimmunity
chemical and pharmacologic phenomena
Review Article
Gene editing
PERIPHERAL-BLOOD
medicine.disease_cause
Immunotherapy, Adoptive
T-Lymphocytes, Regulatory
Cell therapy
Autoimmune Diseases
RNA interference
Immune system
medicine
Humans
Immunology and Allergy
Autologous transplantation
ADOPTIVE TRANSFER
SUPPRESSIVE FUNCTION
CUTTING EDGE
TRANSCRIPTION FACTOR FOXP3
business.industry
COVID-19
Peripheral tolerance
Regulatory T cells
FUNCTIONAL DEFECTS
General Medicine
medicine.disease
EX-VIVO
medicine.anatomical_structure
REMITTING MULTIPLE-SCLEROSIS
Immunology
TH17 CELLS
business
Ex vivo
Subjects
Details
- ISSN :
- 15590267
- Volume :
- 62
- Database :
- OpenAIRE
- Journal :
- Clinical Reviews in Allergy & Immunology
- Accession number :
- edsair.doi.dedup.....0f7ea35d73ab6f3fb9898ee8af40bf15
- Full Text :
- https://doi.org/10.1007/s12016-021-08866-1